Thursday, June 02, 2011 2:27:26 PM
The delivery included over $300,000 of the company's signature DNA-based products. Gulf Coast is a pharmaceutical supply company specializing in the nationwide distribution of pharmaceuticals and medical supplies to the healthcare industry.
"This initial delivery of our products is the first of what we project to be many, under our Agreement with Gulf Coast. Gulf Coast will sell our products to its current base of consumers, hospitals, general practitioners and cardiologists," said Gary Berthold, CEO of InoLife. "We believe our Genetic Predisposition Test is superior to those in the marketplace and we expect it will continue to receive broad acceptance as Gulf Coast markets this first delivery of inventory for re-sale This DNA test reveals genetic predispositions for 25 diseases and conditions in five major categories. Gulf Coast will also distribute InoLife's Cytochrome CYP2C19drug metabolism analysis, a test that determines if a patient has a genetic variation that may reduce the effectiveness of Plavix. If that patient has the genetic variation, the risk of having a stroke, heart attack or other serious cardiac event is higher.
J2 who?
[chart]img229.imageshack.us/img229/4444/catshooting1pe.gif/[chart]
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM